Revenue Growth
The company reported third quarter revenues of $50.2 million, representing 11% growth over the third quarter of 2024.
Adjusted EBITDA Improvement
Adjusted EBITDA improved by 49% compared to the prior year, with a third quarter adjusted EBITDA loss of $2.6 million compared to $5.1 million in Q3 2024.
Expansion of Product Portfolio
Treace Medical has developed and commercialized 3 new bunion correction systems, broadening their product offerings to address nearly 100% of surgeon preferences for bunion correction.
Sales Team Expansion
The company brought on a Chief Commercial Officer and a new Senior Vice President of Sales, adding leading foot and ankle sales experts to their sales team.
Increased Liquidity
Total liquidity as of September 30, 2025, was $80.6 million, marking a decrease in cash usage by 17% in Q3 2025 compared to the prior year.